The Ministry of Health approved funding in the National Health System first and only treatment which provides effective and sustainable reduction in cholesterol levels With two doses per year.

According to the pharmaceutical company Novartis, inclisiran, the active ingredient in Lequio, already approved in Europe, provides effective and sustained cholesterol reduction in 54% of patients with atherosclerotic cardiovascular disease, added to the maximum tolerated dose of statins and at maintenance administration by subcutaneous injection Twice a year.

Medicine interferes with RNA and limits the production of LDL (bad cholesterol). When used, patients with hypercholesterolemia may regulate cholesterol levels in the blood below 100 mg/dl.

In Spain, cardiovascular diseases are the leading cause of death

Cholesterol is natural fat that circulates in the bloodbut if the level is above 200 mg/dL, it can cause cardiovascular disease.

In Spain, cardiovascular diseases are the leading cause of death. According to INE, 119,196 people died from these diseases in 2021, representing 26.4% of total deaths.

Except, Cardiovascular disease is the leading cause of hospitalization (12.9%) in 2021, with 582,446 people admitted to public hospitals.